Herceptin: mechanisms of action and resistance.

[1]  G. Arpino.  Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restoretamoxifen inhibition , 2006 .

[2]  P. Carter,et al.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies , 1993, Cancer Immunology, Immunotherapy.

[3]  F. Esteva,et al.  Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies , 2005, Breast Cancer Research.

[4]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[5]  S. Ménard,et al.  Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.

[6]  G. Hortobagyi,et al.  Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Yarden,et al.  Differences in response of breast cancer molecular profiles of patients likely to respond to either tyrosine kinase inhibitors or to erbB targeted therapies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[9]  F. Esteva.  Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. , 2004, The oncologist.

[10]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[11]  D. Slamon,et al.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.

[12]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[13]  M. Hung,et al.  The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells , 2004, Cancer Research.

[14]  R. Neumann,et al.  Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[15]  M. Willingham,et al.  Development of Herceptin resistance in breast cancer cells , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[16]  Jaakko Astola,et al.  Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines , 2004, Oncogene.

[17]  T. Kute,et al.  DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines* , 2001, Breast Cancer Research and Treatment.

[18]  S. Eccles.  The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[19]  M. Untch,et al.  HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer , 2001, Breast Cancer Research and Treatment.

[20]  Jan M. Rabaey,et al.  Comparison of Methods , 2004 .

[21]  Naoto T Ueno,et al.  P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. , 2004, Cancer research.

[22]  R. Nahta,et al.  HER-2-targeted therapy: lessons learned and future directions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Dihua Yu,et al.  Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone , 2003, Cancer.

[24]  E. Winer,et al.  Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Yee,et al.  Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  R. Bast,et al.  The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition* , 2003, Journal of Biological Chemistry.

[27]  Mikael Lundin,et al.  Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  A. M. Stanley,et al.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.

[29]  G. Hortobagyi,et al.  Growth factor receptors in breast cancer: potential for therapeutic intervention. , 2003, The oncologist.

[30]  Barbara L. Smith,et al.  Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Keefe,et al.  Trastuzumab‐associated cardiotoxicity , 2002, Cancer.

[32]  Hong Ma,et al.  Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.

[33]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[34]  Jinha M. Park,et al.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Arteaga,et al.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.

[36]  Richard J Lee,et al.  Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. , 2002, Molecular cancer therapeutics.

[37]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[39]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[40]  D. Yee.  The insulin-like growth factor system as a treatment target in breast cancer. , 2002, Seminars in oncology.

[41]  D. W. Fry,et al.  Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. , 2002, Seminars in oncology.

[42]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Cheever,et al.  Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  E. Schmidt,et al.  Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. , 2002, Cancer research.

[45]  Terry L. Smith,et al.  Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[47]  M. Bilous.  Predicting HER2 status of breast cancer from basic pathology features: HER2 status of 1500 breast cancers determined by immunohistochemistry and flourescence In situ hybridisation with pathology correlation , 2002 .

[48]  E. McDermott,et al.  Anti‐human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer , 2002, The British journal of surgery.

[49]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  K. Knutson,et al.  Vaccination against the HER-2/neu oncogenic protein. , 2002, Endocrine-related cancer.

[51]  J. Garcia-conde,et al.  NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer , 2002 .

[52]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Y. Tokuda,et al.  [Trastuzumab (Herceptin)]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[54]  D. Slamon,et al.  HER2 testing and correlation with efficacy of trastuzumab therapy. , 2002, Oncology.

[55]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[56]  R. Bianco,et al.  Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.

[57]  M. Dowsett,et al.  Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  E. Winer,et al.  New Combinations with Herceptin® in Metastatic Breast Cancer , 2001, Oncology.

[59]  J. Baselga,et al.  Mechanism of action of trastuzumab and scientific update. , 2001, Seminars in oncology.

[60]  K. Lackey,et al.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. , 2001, Cancer research.

[61]  G. Hortobagyi,et al.  Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[63]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[64]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  K S Panageas,et al.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  W. Eiermann,et al.  Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene , 2001 .

[67]  D. Berry,et al.  Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[69]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  H. Lane,et al.  Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  A. Ebert,et al.  Current use of HER2 tests. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  J. Baselga.  Phase I and II clinical trials of trastuzumab. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[74]  D. Slamon,et al.  Trastuzumab and chemotherapeutics: drug interactions and synergies. , 2000, Seminars in Oncology.

[75]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Rosenblum,et al.  A novel recombinant fusion toxin targeting HER‐2/NEU–over‐expressing cells and containing human tumor necrosis factor , 2000, International journal of cancer.

[77]  S. Mader,et al.  Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis , 2000, Oncogene.

[78]  B. Lloveras,et al.  Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  John M. Daly,et al.  ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.

[80]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[81]  M. Bui,et al.  Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. , 2000, Annals of clinical and laboratory science.

[82]  Jeffrey S. Miller,et al.  Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. , 1999, Experimental hematology.

[83]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[85]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[87]  M. Rosenblum,et al.  Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  J. Poen,et al.  Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. , 1999, Cancer research.

[89]  J. Doherty,et al.  NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.

[90]  R. Finn,et al.  Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.

[91]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[92]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[93]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[95]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[97]  I. Pastan,et al.  The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. , 1996, Seminars in cancer biology.

[98]  R. Cardiff,et al.  Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.

[99]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  L. Weiner,et al.  Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII , 1995 .

[101]  M. Hung,et al.  Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. , 1995, Oncogene.

[102]  L. Weiner,et al.  Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. , 1995, Journal of hematotherapy.

[103]  V. Chinchilli,et al.  Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  P. Carter,et al.  Bispecific HER2 × CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice , 1995 .

[105]  L. Weiner,et al.  Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. , 1995, Cancer research.

[106]  P. Carter,et al.  Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. , 1995, Clinical immunology and immunopathology.

[107]  D. Slamon,et al.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.

[108]  I. Pastan,et al.  Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide‐stabilized anti‐TAC Fv fragment and truncated pseudomonas exotoxin , 1994, International journal of cancer.

[109]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[110]  S. Ménard,et al.  The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. , 1993, Oncogene.

[111]  T. Singleton,et al.  Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.

[112]  G. Adams,et al.  A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. , 1993, Cancer research.

[113]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[114]  B. Groner,et al.  Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. , 1992, Cancer research.

[115]  I. Pastan,et al.  Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[116]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Lin Yz,et al.  A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. , 1991 .

[118]  W. Carney,et al.  The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. , 1991, The Journal of biological chemistry.

[119]  G. Clinton,et al.  A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. , 1991, Oncogene.

[120]  M. Hung,et al.  Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[121]  J. Bausch,et al.  Monoclonal antibodies. , 1990, Bioprocess technology.

[122]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[124]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[125]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[126]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.